A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2006
11/21/2006	CA2511750C Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
11/21/2006	CA2334843C Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics
11/21/2006	CA2204478C Fluorinated vitamin d3 analogs
11/21/2006	CA2120619C Novel potent inducers of terminal differentiation and methods of use thereof
11/21/2006	CA2078003C Tumor killing effects of enterotoxins and related compounds
11/20/2006	CA2611370A1 Inhibitors of vegf receptor and hgf receptor signaling
11/18/2006	CA2547251A1 Fused pyrazolyl compounds for cancer treatment
11/16/2006	WO2006122274A2 Pharmaceutical formulations of rhodiola crenulata and methods of use thereof
11/16/2006	WO2006122137A1 1, 6 -dihydro- 1,3, 5, 6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same as inhibitors of ikk enzyme activity
11/16/2006	WO2006121263A1 Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization
11/16/2006	WO2006121219A1 Agent for controlling epithelial-mesenchymal transition
11/16/2006	WO2006121159A1 Humanized cdr-grafted antibody specifically reacting with cd10 and antibody fragment of the same
11/16/2006	WO2006121097A1 Bicyclic heterocyclic derivative or salt thereof
11/16/2006	WO2006121095A1 Substituted acrylamide derivative and pharmaceutical composition comprising the same
11/16/2006	WO2006120580A2 Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
11/16/2006	WO2006120568A2 Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone
11/16/2006	WO2006120564A1 Pharmaceutical composition comprising an antiviral agent, an antitumoral agent or an antiparasitic agent, and an active agent selected among carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120557A1 Anticancer combination therapy using sunitinib malate
11/16/2006	WO2006120495A1 Pharmaceutical composition comprising an antiviral agent, an antitumour agent or an antiparasitic agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120456A1 Pharmaceutical formulations of hdac inhibitors
11/16/2006	WO2006120160A1 Use of an immunoglobulin domain-containing cell surface recognition molecule for treating diseases
11/16/2006	WO2006120120A1 Use of docosahexaenoic glycerides for the treatment of tumorous diseases
11/16/2006	WO2006120104A1 Inhibitors of prolyl endopeptidase
11/16/2006	WO2006119968A2 Compositions and methods using microspheres and non-ionic contrast agents
11/16/2006	WO2006119783A1 Production of anticancer compound from oyster mushroom fruit bodies
11/16/2006	WO2006119782A1 Anticancer effect of polysaccharides occuring in pleurotus ostreatus mycelia
11/16/2006	WO2006119736A2 Pdz-domain modulators
11/16/2006	WO2006119706A1 Auxiliary method for diagnosis and therapy of cancer with nucleolin
11/16/2006	WO2006119676A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
11/16/2006	WO2006119675A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
11/16/2006	WO2006119674A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
11/16/2006	WO2006119673A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
11/16/2006	WO2006119619A1 Oligonucleotides inhibiting cell proliferation
11/16/2006	WO2006061253A3 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
11/16/2006	WO2006031370A3 Polypeptide variants with altered effector function
11/16/2006	WO2006029183A3 Compositions and methods for the diagnosis and treatment of tumor
11/16/2006	WO2006002895A3 Conjugates of antibody and duoarmycin derivatives as antitumor agents
11/16/2006	WO2006000589A8 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
11/16/2006	US20060258744 Medicament for preventing and/or treating peripheral neuropathies
11/16/2006	US20060258731 Antitumor compound and therapeutic uses thereof
11/16/2006	US20060258724 Anticoagulants; cardiovascular disorders; atherosclerosis; antiarthritic agents; Alzheimer's disease; anticancer agents
11/16/2006	US20060258658 Triazole compounds useful as protein kinase inhibitors
11/16/2006	US20060258656 Compositions and methods for treating cancer
11/16/2006	US20060258651 Use of heterocyclic compounds as scce inhibitors
11/16/2006	US20060258642 Confining solid tumors; administering a tyrosine kinase inhibitor as antitumor agents; 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
11/16/2006	US20060258606 Transforming growth factor-beta response element decoys and methods
11/16/2006	US20060258595 Apoptosis of rectum and prostate gland cancer
11/16/2006	US20060258585 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
11/16/2006	US20060258572 Somatostatin-dopamine chimeric analogs
11/16/2006	US20060258566 Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use
11/16/2006	US20060258563 Nitrogen Oxide scavenging ability; digesting cytochrome c with restriction enzyme; use in prophylactic and therapeutics, measuring/treating nitrogen oxide concentrations in air, exhaust gas or water
11/16/2006	US20060257989 Truncated aggrecanase molecules
11/16/2006	US20060257965 Extracellular matrix signalling molecules
11/16/2006	US20060257911 Of given nucleotide sequence; diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders
11/16/2006	US20060257882 Novel polynuceotides and polypeptides encoded thereby
11/16/2006	US20060257432 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucelic acid replication
11/16/2006	US20060257431 Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
11/16/2006	US20060257427 Molecule (antibody, peptide or chemical), coupled to a detectable label, cytotoxic agent or solid support, that specifically binds an extracellular portion of the latent viral membrane bound protein of Epstein-Barr Virus expressed in the latent viral membrane in the latent life cycle
11/16/2006	US20060257401 Sensitizing cells for apoptosis by selectively blocking cytokines
11/16/2006	US20060257367 Tumour-cell specific gene expression and its use in cancer therapy
11/16/2006	US20060257366 Chimeric glycoproteins and pseudotyped lentiviral vectors
11/16/2006	US20060257362 Method and composition for preventing and reating solid tumors
11/16/2006	US20060257330 Powdery pharmaceutical compositions for inhalation
11/16/2006	DE102005023301A1 Medicament used to reduce risk of e.g. heart disease and urinary tract disease, comprises 5-methyl-(6S)-tetrahydrofolate, estrogen and/or gestagene, vitamin B6 and/or vitamin B2 and auxiliary or carrier materials
11/16/2006	DE102005022182A1 Modulatoren der PDZ-Domäne Modulators of the PDZ domain
11/16/2006	CA2840609A1 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
11/16/2006	CA2614192A1 Use of docosahexaenoic glycerides for the treatment of tumoral diseases
11/16/2006	CA2608061A1 Pharmaceutical composition including an anti-tumoral and an active ingredient selected among carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	CA2607954A1 Conjugate for targeting of drug
11/16/2006	CA2607832A1 Auxiliary method for diagnosis and therapy of cancer with nucleolin
11/16/2006	CA2607806A1 Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
11/16/2006	CA2607228A1 Compositions and methods using microspheres and non-ionic contrast agents
11/16/2006	CA2606887A1 Pharmaceutical composition
11/16/2006	CA2606598A1 Pharmaceutical formulations of hdac inhibitors
11/16/2006	CA2606287A1 Peptide
11/16/2006	CA2603445A1 Anticancer combination therapy using sunitinib malate
11/15/2006	EP1721987A1 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
11/15/2006	EP1721903A1 Compositions and therapeutic methods involving isoflavones and analogues thereof
11/15/2006	EP1721901A1 Abc transporter inhibitor
11/15/2006	EP1721618A2 Proteosome influenza vaccine composition
11/15/2006	EP1721615A1 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
11/15/2006	EP1721610A1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
11/15/2006	EP1720994A1 Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same
11/15/2006	EP1720889A1 Sulfated oligosaccharide derivatives
11/15/2006	EP1720883A1 Pyrazolotriazines as kinase inhibitors
11/15/2006	EP1720882A2 Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
11/15/2006	EP1720881A1 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
11/15/2006	EP1720880A1 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4]benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs thereof as well as related compounds for the treatment of proliferative diseases
11/15/2006	EP1720874A1 4-substituted piperidine derivatives
11/15/2006	EP1720862A1 Kinase inhibitors
11/15/2006	EP1720849A1 Pyranone derivatives useful for treating cancer
11/15/2006	EP1720848A1 Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
11/15/2006	EP1720845A1 Isothiourea derivatives
11/15/2006	EP1720844A2 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
11/15/2006	EP1720843A2 Process for the preparation of substituted triazole compounds
11/15/2006	EP1720613A2 Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
11/15/2006	EP1720612A2 Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
11/15/2006	EP1720611A2 Diagnostic marker for cancer
11/15/2006	EP1720565A1 Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
11/15/2006	EP1720540A2 Methods for treating resistant or refractory tumors

1 ... 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 ... 2211